HSBC Holdings
ZVRA icon

HSBC Holdings’s Zevra Therapeutics ZVRA Stock Holding History

HSBC Holdings’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.24M Buy
+154,414
New +$1.72M ﹤0.01% 1546

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

HSBC Holdings's ZVRA Position: Q2 2026 in Review

HSBC Holdings opened a new position in Zevra Therapeutics (ZVRA) in Q2 2026: 154,414 shares worth $2.24M. The stake represents ﹤0.01% of the portfolio and ranks #1546 among its holdings.

157 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

  • HSBC Holdings held 154,414 shares of Zevra Therapeutics worth $2.24M as of Q2 2026.
  • Zevra Therapeutics was a new HSBC Holdings position in Q2 2026.
  • Zevra Therapeutics made up ﹤0.01% of HSBC Holdings's portfolio in Q2 2026, its #1546 holding.
  • 157 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on HSBC Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.